Search Everything in One Place

Explore the web, images, videos, news, and more – all in one place.

🌐 Web 🖼️ Images 🎥 Videos 📰 News 🛍️ Shopping

Health

Gentherm acquires medical device maker IME to expand healthcare portfolio

Seeking Alpha · Jul 22, 2026 20:19 · 1 min read

Helios Towers reports Q1 results — Gentherm acquires medical device maker IME to expand healthcare portfolio

Gentherm (THRM) said on Wednesday it acquired privately held Innovative Medical Equipment (IME), adding the ThermaZone thermal therapy device to expand its medical products business. The company said the acquisition broadens its healthcare product portfolio and customer base. More on Gentherm Gentherm Incorporated (THRM) Presents at 2026 Baird Glo...

Gentherm (THRM) said on Wednesday it acquired privately held Innovative Medical Equipment (IME), adding the ThermaZone thermal therapy device to expand its medical products business.
The company said the acquisition broadens its healthcare product portfolio and customer base.

More on Gentherm

Tags: Health Health news Business Money

Read full story on Seeking Alpha

Related News

More stories you might be interested in.

Here are the major earnings before the open Thursday

Seeking Alpha·30 minutes ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: Lockheed Martin Corporation (LMT) RTX Corporation (RTX) Nokia Oyj (NOK) Freeport-McMoRan (FCX) Blackstone (BX) Other earnings slated for release before Thursday's open include: AAL, ACI, ALLE, AMBP, AMP, ARGX, ASPS, BESIY, BFH, BNPQY, BPOP, CLF, CMCSA, COCO, CX, DASTY, DGX...

Elon Musk talks up Tesla's upside with Optimus, Megapods, and robotaxis

Seeking Alpha·36 minutes ago

Elon Musk talks up Tesla's upside with Optimus, Megapods, and robotaxis

Tesla (TSLA) swung lower after the company reported record revenue and deliveries for its second quarter but also saw negative free cash flow for the first time in two years as $5.8B in capital expenditure spending factored in. During the earnings conference call, Musk led off by talking about the strong uptake of FSD and long-term upside. He noted...

Seeking Alpha·42 minutes ago

Popular Q2 2026 earnings preview

Popular (BPOP) is scheduled to announce Q2 earnings results on Thursday, July 23rd, before market open. The consensus EPS estimate is $3.68, and the consensus revenue estimate is $848.6M (+6.1% Y/Y). Over the last year, BPOP has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time. Over the last 3 months, EPS estima...

Seeking Alpha·43 minutes ago

FirstCash Q2 2026 earnings preview

FirstCash (FCFS) is scheduled to announce Q2 earnings results on Thursday, July 23rd, during the market. The consensus EPS estimate is $2.39 (+33.5% Y/Y), and the consensus revenue estimate is $1.03B (+24.0% Y/Y). Over the last 2 years, FCFS has beaten EPS estimates 100% of the time and has beaten revenue estimates 75% of the time. Over the last 3 ...

Billionaire Michael Bloomberg says Trump’s plan to have the government own AI would make George Orwell blush

Moneywise·4 hours ago

Billionaire Michael Bloomberg says Trump’s plan to have the government own AI would make George Orwell blush

Trump is reportedly weighing government ownership stakes in AI firms like OpenAI.

Cathie Wood's $362 million CRISPR Therapeutics bet isn't just bold -- it's backed by a catalyst many investors are underrating

The Motley Fool·12 hours ago

Cathie Wood's $362 million CRISPR Therapeutics bet isn't just bold -- it's backed by a catalyst many investors are underrating

This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far.

Innate Pharma concludes enrolment in dose escalation of IPH4502 study

GlobalData·11 hours ago

Innate Pharma concludes enrolment in dose escalation of IPH4502 study

The open-label, multi-centre trial is being carried out at sites in France and the US.

FDA panel to review popular peptides amid persistent consumer appetite

Reuters·6 hours ago

FDA panel to review popular peptides amid persistent consumer appetite

By Sneha S K and Sriparna Roy July 22 (Reuters) - U.S. FDA advisers this week will weigh whether seven popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry participants say consumer demand is likely to remain strong. The review comes as peptides move out of niche anti-aging clinics into the burgeoning wellness market, fueled by

Samsung unveils new foldable phone. See price, design and release date

USA TODAY·7 hours ago

Samsung unveils new foldable phone. See price, design and release date

The new Galaxy Z Fold8 is available for pre-order starting July 22.

Parkinson’s Isn’t Just Bad Luck. Scientists Reveal It’s Largely Preventable—and the Culprit Is All Around Us

Oprah Daily·11 months ago

Parkinson’s Isn’t Just Bad Luck. Scientists Reveal It’s Largely Preventable—and the Culprit Is All Around Us

We talked to two doctors intent on making the neurodegenerative disease obsolete.

Sign in

Sign up